Biopharma Dealmakers
Latest Publications

TOTAL DOCUMENTS

40

(FIVE YEARS 40)

H-INDEX

0

(FIVE YEARS 0)

Published By Springer Science And Business Media LLC

2730-6275, 2730-6283

Latest Documents Most Cited Documents Contributed Authors Related Sources Related Keywords

Biopharma financing digest—Winter 2021

Biopharma Dealmakers ◽

10.1038/d43747-021-00178-9 ◽

2021 ◽

Author(s):

Emma Dorey

Download Full-text

Opportunities to target mast cells in inflammatory diseases expand

Biopharma Dealmakers ◽

10.1038/d43747-021-00176-x ◽

2021 ◽

Author(s):

Mark Zipkin

Keyword(s):

Inflammatory Diseases

Download Full-text

High-value rare disease R&D deals of 2021

Biopharma Dealmakers ◽

10.1038/d43747-021-00161-4 ◽

2021 ◽

Author(s):

Raveena Bhambra ◽

DealForma, LLC

Keyword(s):

Download Full-text

Targeting antimicrobial resistance

Biopharma Dealmakers ◽

10.1038/d43747-021-00147-2 ◽

2021 ◽

Author(s):

Raveena Bhambra

Keyword(s):

Antimicrobial Resistance

Download Full-text

‘Business of science’ digest—October 2021

Biopharma Dealmakers ◽

10.1038/d43747-021-00146-3 ◽

2021 ◽

Author(s):

Raveena Bhambra

Download Full-text

‘Business of science’ digest—July and August 2021

Biopharma Dealmakers ◽

10.1038/d43747-021-00145-4 ◽

2021 ◽

Author(s):

Raveena Bhambra

Download Full-text

Top ten biopharma M&As of 2021

Biopharma Dealmakers ◽

10.1038/d43747-021-00107-w ◽

2021 ◽

Author(s):

Biopharma Dealmakers

Download Full-text

Chasing immune checkpoint inhibitors

Biopharma Dealmakers ◽

10.1038/d43747-021-00110-1 ◽

2021 ◽

Author(s):

Raveena Bhambra

Keyword(s):

Immune Checkpoint ◽

Immune Checkpoint Inhibitors ◽

Checkpoint Inhibitors

Download Full-text

Next-generation therapeutics thrust into the spotlight

Biopharma Dealmakers ◽

10.1038/d43747-021-00105-y ◽

2021 ◽

Author(s):

Paul Verdin ◽

Tsz Mon Tsang

Keyword(s):

Next Generation

Download Full-text

Biopharma financing digest—August 2021

Biopharma Dealmakers ◽

10.1038/d43747-021-00143-6 ◽

2021 ◽

Author(s):

Emma Dorey

Download Full-text